Metformin versus levonorgestrel-releasing intrauterine system in the management of endometrial hyperplasia: a randomized clinical trial

Middle East Fertility Society Journal

Table 2 The histopathological outcome of uterine biopsy after the intervention

Variables	Mirena group (n = 25)	Metformin group (n = 25)	Test value	p-value
Regression	24 (96%)	16 (64%)	8.3	0.009^a
- Scanty proliferative endometrium	8 (33.3%)	14 (56%)
- Arrest of secretions after hormonal therapy	16 (66.7%)	0 (0%)
- Irregular secretory/proliferative endometrium	0 (0%)	2 (8%)
Persistent hyperplasia	1 (4%)	9 (36%)

Two patients with failed treatment in the metformin group had hysterectomy based upon their request. The remaining 7 had oral progestogen together with Metformin. The only patient with persistent hyperplasia in the Mirena group was counseled to continue treatment for 12 months
^ap-values are based on the Fisher Exact test. Statistical significance at P < 0.05